Precision oncology company developing small molecule drugs that are targeted at particular mutations. Led by CEO Gary Glick (former CEO of IFM, IFM Tre, IFM Due, and an Abingworth Senior Advisor), alongside founders Keith Flaherty, Gad Getz and Liron Bar-Peled (all of Harvard Medical School and Massachusetts General Hospital).

LocationCambridge, MA
CEOAxel Hoos
Partner Tim Haines